- Home
- PLAY vs CTNM Comparison
PLAY vs CTNM Comparison
Compare PLAY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLAY | CTNM |
|---|---|---|
| Founded | 1982 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.5M | 507.0M |
| IPO Year | 2011 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PLAY | CTNM |
|---|---|---|
| Price | $12.33 | $13.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $25.29 | $19.00 |
| AVG Volume (30 Days) | ★ 1.7M | 335.6K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.19 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.61 | $3.35 |
| 52 Week High | $35.38 | $16.33 |
Technical Indicators
Market Signals| Indicator | PLAY | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.87 | 50.14 |
| Support Level | N/A | $10.17 |
| Resistance Level | $13.92 | $15.80 |
| Average True Range (ATR) | 0.99 | 1.01 |
| MACD | 0.11 | 0.08 |
| Stochastic Oscillator | 62.35 | 68.75 |
Price Performance
Historical ComparisonAbout PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.